The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis
Open accessAbstract
Summary Background The Meta-Analysis of Radiotherapy in squamous cell Carcinomas of Head and neck (MARCH) showed that altered fractionation radiotherapy is associated with improved overall and progression-free survival compared with conventional radiotherapy, with hyperfractionated radiotherapy showing the greatest benefit. This update aims to confirm and explain the superiority of hyperfractionated radiotherapy over other altered fractionation radiotherapy regimens and to assess the benefit of altered fractionation within the context of concomitant chemotherapy with the inclusion of new trials. Methods For this updated meta-analysis, we searched bibliography databases, trials registries, and meeting proceedings for published or unpublished randomised trials done between Jan 1, 2009, and July 15, 2015, comparing primary or postoperative conventional fractionation radiotherapy versus altered fractionation radiotherapy (comparison 1) or conventional fractionation radiotherapy plus concomitant chemotherapy versus altered fractionation radiotherapy alone (comparison 2). Eligible trials had to start randomisation on or after Jan 1, 1970, and completed accrual before Dec 31, 2010; had to have been randomised in a way that precluded prior knowledge of treatment assignment; and had to include patients with non-metastatic squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx undergoing first-line curative treatment. Trials including a non-conventional radiotherapy control group, investigating hypofractionated radiotherapy, or including mostly nasopharyngeal carcinomas were excluded. Trials were grouped in three types of altered fractionation: hyperfractionated, moderately accelerated, and very accelerated. Individual patient data were collected and combined with a fixed-effects model based on the intention-to-treat principle. The primary endpoint was overall survival. Findings Comparison 1 (conventional fractionation radiotherapy vs altered fractionation radiotherapy) included 33 trials and 11 423 patients. Altered fractionation radiotherapy was associated with a significant benefit on overall survival (hazard ratio [HR] 0·94, 95% CI 0·90–0·98; p=0·0033), with an absolute difference at 5 years of 3·1% (95% CI 1·3–4·9) and at 10 years of 1·2% (−0·8 to 3·2). We found a significant interaction (p=0·051) between type of fractionation and treatment effect, the overall survival benefit being restricted to the hyperfractionated group (HR 0·83, 0·74–0·92), with absolute differences at 5 years of 8·1% (3·4 to 12·8) and at 10 years of 3·9% (−0·6 to 8·4). Comparison 2 (conventional fractionation radiotherapy plus concomitant chemotherapy versus altered fractionation radiotherapy alone) included five trials and 986 patients. Overall survival was significantly worse with altered fractionation radiotherapy compared with concomitant chemoradiotherapy (HR 1·22, 1·05–1·42; p=0·0098), with absolute differences at 5 years of −5·8% (−11·9 to 0·3) and at 10 years of −5·1% (−13·0 to 2·8). Interpretation This update confirms, with more patients and a longer follow-up than the first version of MARCH, that hyperfractionated radiotherapy is, along with concomitant chemoradiotherapy, a standard of care for the treatment of locally advanced head and neck squamous cell cancers. The comparison between hyperfractionated radiotherapy and concomitant chemoradiotherapy remains to be specifically tested.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
Ang, K. K., Harris, J., Wheeler, R., Weber, R., Rosenthal, D. I., Nguyen-Tân, P. F., Westra, W. H., Chung, C. H., Jordan, R. C., Lu, C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912217 · Cited by 6,566
Self-citationBeta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Pignon, J.-P., Maître, A. L., Maillard, E., & Bourhis, J. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.04.014 · Cited by 3,069
Self-citationNon-small Cell Lung Cancer Collaborative Group (1995) · BMJ · doi:10.1136/bmj.311.7010.899 · Cited by 2,850
A note on quantifying follow-up in studies of failure time
Schemper, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,575
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
Early Breast Cancer Trialist's Collaborative Group (1992) · The Lancet · doi:10.1016/0140-6736(92)90997-h · Cited by 2,182
Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis
Bourhis, J., Overgaard, J., Audry, H., Ang, K. K., Saunders, M., Bernier, J., Horiot, J.-C., Le Maître, A., Pajak, T. F., Poulsen, M. G., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69121-6 · Cited by 1,085
Self-citation
Cited by
Chow, L. Q. M. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1715715 · Cited by 2,075
Machiels, J.-P., René Leemans, C., Golusinski, W., Grau, C., Licitra, L., & Gregoire, V. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.011 · Cited by 916
Self-citationThe changing therapeutic landscape of head and neck cancer
Cramer, J. D., Burtness, B., Le, Q. T., & Ferris, R. L. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0227-z · Cited by 783
Self-citationLacas, B., Carmel, A., Landais, C., Wong, S. J., Licitra, L., Tobias, J. S., Burtness, B., Ghi, M. G., Cohen, E. E. W., Grau, C., et al. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.01.013 · Cited by 389
Self-citation(2024) · doi:10.7554/elife.87873.3 · Cited by 6
Metadata
- Authors
- Lacas, B., Bourhis, J., Overgaard, J., Zhang, Q., Grégoire, V., Nankivell, M., Zackrisson, B., Szutkowski, Z., Suwiński, R., Poulsen, M., O'Sullivan, B., Corvò, R., Laskar, S. G., Fallai, C., Yamazaki, H., Dobrowsky, W., Cho, K. H., Beadle, B., Langendijk, J. A., Viegas, C. M. P., Hay, J., Lotayef, M., Parmar, M. K. B., Aupérin, A., van Herpen, C., Maingon, P., Trotti, A. M., Grau, C., Pignon, J.-P., Blanchard, P., Blanchard, P., Bourhis, J., Lacas, B., Pignon, J. P., Bernier, J., Le, Q.-T., Overgaard, J., Parmar, M. K., Trotti, A., Agarwal, J. P., Aupérin, A., Ang, K. K., Awwad, H. K., Bacigalupo, A., Bartelink, H., Benhamou, E., Bernier, J., Blanchard, P., Bourhis, J., Budach, W., Chitapanarux, I., Cho, K. H., Collette, L., Corvò, R., Dani, C., Dische, S., Dobrowsky, W., Denham, J. W., Driessen, C. M., Fallai, C., Beadle, B., Laskar, S. G., Ghoshal, S., Grau, C., Gregoire, V., Hay, J. H., van Herpen, C., Hliniak, A., Johansen, J., Kristiansen, C. A., Krstevska, V., Lacas, B., Langendijk, J. A., Lapeyre, M., Le, Q.-T., Lotayef, M., Maciejewski, B., Maingon, P., Michalski, W., Moon, S. H., Nilsson, P., Olmi, P., Nankivell, M., Nishiyama, K., O'Sullivan, B., Overgaard, J., Parmar, M. K., Pignon, J.-P., Poulsen, M. G., Ramadas, K., Rishi, A., Rosenthal, D. I., Sanguineti, G., Saunders, M. I., Sire, C., Skladowski, K., Souhami, L., Suwinski, R., Szutkowski, Z., Tandon, N., van Tinteren, H., Torri, V., Tripcony, L., Trotti, A., Viegas, C. M. P., Waldron, J., Widder, J., Wong, S., Wu, J. S., Yamazaki, H., Zackrisson, B., & Zhang, Q.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 18
- Issue
- 9
- Pages
- 1221-1237
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2740402187
- Cited by
- 345
- References
- 37
- FWCI
- 27.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. https://app.cochat.ai/papers/10.1016/s1470-2045(17)30458-8
- The paper
- Lacas, B., Bourhis, J., Overgaard, J., Zhang, Q., Grégoire, V., Nankivell, M., Zackrisson, B., Szutkowski, Z., Suwiński, R., Poulsen, M., O'Sullivan, B., Corvò, R., Laskar, S. G., Fallai, C., Yamazaki, H., Dobrowsky, W., Cho, K. H., Beadle, B., Langendijk, J. A., . . . Zhang, Q. (2017). Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(17)30458-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.